Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Orthocell Ltd ( (AU:OCC) ) just unveiled an update.
Orthocell Limited announced its submission of a regulatory application to Health Canada for the approval to sell Remplir in the Canadian market, valued at approximately US$75 million. The company plans to expand further into major markets, including the US, Thailand, the UK, the EU, and Brazil in 2025, aiming to capture a significant share of the US$3.2 billion global market for nerve repair. With a strong balance sheet and strategic market entries, Orthocell is poised for substantial growth, targeting a 20% share in the addressed markets and leveraging experienced executives to enhance its go-to-market strategy.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company based in Perth, Australia, specializing in nerve repair products. Their primary product, Remplir, is a collagen wrap used in nerve repair surgeries. The company focuses on expanding its market reach, targeting significant markets such as Australia, New Zealand, Singapore, and others globally.
YTD Price Performance: 15.44%
Average Trading Volume: 1,640,010
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$376.7M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.
